Recent news on Gefitinib

Shedding Light on Acquired Treatment Resistance in Lung Cancer  -  Apr 26, 2007
Cancerpage.com,Gefitinib and erlotinib are used to treat non-small cell lung cancers with activating mutations in the gene for epidermal growth factor receptor.

Neuroscience: Light-headed  -  May 2, 2007
Nature.com (subscription),The drug gefitinib is at first an effective treatment for certain types of lung cancer, but most cancers become resistant to it.

New drug combination for breast cancer patients  -  May 9, 2007
TopCancerNews.com,These 3 drugs are monoclonal antibodies which target certain aspects of tumours( pertuzumab; trastuzumab, also known as Herceptin; and gefitinib,

Drug combination helps certain breast cancer cases  -  May 1, 2007
ReutersThe third drug was gefitinib, sold by AstraZeneca under the brand name Iressa. All the drugs are monoclonal antibodies -- engineered human immune system

Combination treatment stymies breast cancer growth  -  May 14, 2007
SpiritIndia,Adding two other experimental drugs – gefitinib and pertuzumab -- that inhibit HER-2 in different ways can more completely block the growth signals in the

Lung Cancer is the Third Most Common Malignant Disease and the ...  -  May 13, 2007
Fuerteventura Digital,Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments.

Tamoxifen Protects Certain Women at High Risk for Breast Cancer  -  May 2, 2007
Forbes,The team added two cancer drugs, gefitinib and pertuzumab, to Herceptin (trastuzumab) to help slow the growth of tumors with higher levels of a protein

Drug combination helps certain breast cancer cases  -  May 1, 2007
ReutersThe third drug was gefitinib, sold by AstraZeneca (AZN.L: Quote, Profile, Research under the brand name Iressa. All the drugs are monoclonal antibodies

Drug Combination Halts Tumor Growth Better Than Single Agent  -  May 2, 2007
Medical News Today (press release),Some mice received one of three HER inhibitors - pertuzumab, trastuzumab, or gefitinib - or a combination of two or three of the drugs.

Treatment Strategy For Patients With Resistant Lung Tumors  -  May 2, 2007
Medical News Today (press release),Drugs like Iressa (gefitinib) and Tarceva (erlotinib) are used to treat advanced non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths in

Ireland Cancer Center Researchers Advance Lung Cancer Treatment  -  Apr 28, 2007
Medical News Today (press release),...that desensitizes the response to Tarceva (erlotinib) but yet differentially sensitized the response to another medication, Iressa (gefitinib), further.

Scientists Spot Mechanism Behind Lung Cancer Drug Resistance  -  Apr 26, 2007
Atlanta Journal Constitution (subscription),Doctors often resort to drugs such as Iressa (gefitinib) and Tarceva (erlotinib) to treat advanced non-small-cell lung cancer. These agents work by blocking

Mechanism produces resistance  -  Apr 26, 2007
France24,Tarceva (eriotinib) and Iressa (gefitinib) are used to treat advanced types of lung cancer, the leading cause of cancer deaths in the United States.

Mechanism identified for resistance to targeted lung cancer drugs  -  Apr 26, 2007
SpiritIndia,Drugs like Iressa (gefitinib) and Tarceva (erlotinib) are used to treat advanced non-small-cell lung cancer (NSCLC), the leading cause of cancer de aths in

New methods for treating lung cancer cells that have become ...  -  Apr 24, 2007
News-Medical.net,...that desensitizes the response to Tarceva (erlotinib) but yet differentially sensitized the response to another medication, Iressa (gefitinib), further.

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral ...  -  Apr 17, 2007
PharmaLive.com (press release),Erlotinib and gefitinib have no effect on the EGFR L858R/T790M double mutant, which is estimated to account for approximately 50 percent of all drug

Lung Cancer-Derived EGFR Mutants Exhibit Intrinsic Differences In ...  -  Mar 15, 2007
Medical News Today (press release),Structural examination of the inhibitor complexes, which included the drug gefitinib (Iressa), revealed that the mutations can affect the way the inhibitors

How Some Molecules Inhibit Growth Of Lung Cancer Cells Revealed By ...  -  Mar 15, 2007
Medical News Today (press release),..."We now see that inhibitors such as gefitinib actually bind more tightly to some of the cancer-causing mutants, even though they were originally developed

AZs new PR&D centre leverages Indian chemistry expertise  -  Mar 23, 2007
DrugResearcher.com,The decision was predicated on the superior efficacy of Iressa (gefitinib), AstraZeneca's ill-fated treatment for lung cancer, in Asian over Western

Native kinase profiling  -  Mar 21, 2007
DrugResearcher.com,While the majority of kinase inhibitors such as Tykerb, AstraZeneca's Iressa (gefitinib) and Bristol-Myers Squibb's Sprycel (dasatinib) all focus on various

GSK's new breast cancer drug approved  -  Mar 16, 2007
DrugResearcher.com,However, Tykerb is the first drug to target both HER2 and HER1, setting it apart from AstraZenenca's Iressa (gefitinib) - asmall molecule kinase inhibitor

AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R ...  -  Feb 27, 2007
PipelineReview.com (press release),ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind randomized phase II trial. Proceedings of ASCO 2006;

Iressa's efficacy over rival drugs unproved  -  Feb 6, 2007
The Japan Times,The group, which compared Iressa, generically known as gefitinib, in clinical trials against another cancer drug, said "there seems to be no basis for

Infinity and MedImmune Initiate Phase I/II Clinical Trial of IPI ...  -  Feb 15, 2007
PipelineReview.com (press release),..."Targeted therapies such as erlotinib and gefitinib have improved outcomes in many lung cancer patients, but resistance to these agents remains a challenge.

Microsatellite Instability, EGFR Testing, and FISH  -  Feb 2, 2007
Medscape (subscription)While there was initially great excitement over the prospect of selecting candidates for gefitinib therapy by first detecting these EGFR mutations primarily

ImClone Opts Out Of UCB Deal To Develop CDP-791  -  Feb 6, 2007
BioWorld Online,Other EGFR-targeting cancer drugs include Tarceva (erlotinib, Genentech Inc. and OSI Pharmaceuticals Inc.) and Iressa (gefitinib, AstraZeneca plc),

Angel Broking neutral on SMS Pharma IPO  -  Feb 5, 2007
Moneycontrol.com,Apart from this the company has developed non-infringing process for Ramipril, Gemcitibine, Gefitinib. The company has also filed 6 process and 1 product

Exelixis Appoints Jose Baselga, MD, a Leading Expert in Oncology ...  -  Jan 30, 2007
Drug Newswire (press release),He has made significant contributions to the clinical development of several approved targeted cancer therapies, including trastuzumab, cetuximab, gefitinib

Octreotide of No Benefit in Advanced Liver Cancer  -  Jan 26, 2007
Cancerpage.com,..."In this context," he said, "a major area of clinical research is 'targeted HCC therapy' with small molecule inhibitors of tyrosine kinases (gefitinib,

Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and ...  -  Jan 2, 2007
Am J Pathology (subscription)PP1 decreased phosphorylation of EGFR, ErbB2, and ErbB3 and strikingly enhanced apoptosis by gefitinib, an EGFR inhibitor. HCC827 cells transfected with

Telik Drug Disappoints  -  Dec 26, 2006
TheStreet.comThe drug was compared with gefitinib, and it didn't achieve a statistically significant improvement in overall survival, the primary endpoint.

Safe Practice Guidelines for Oral Chemotherapy Found Gravely Lacking  -  Jan 12, 2007
MedPage Today,The drugs included Xeloda (capecitabine), Cytoxan (cyclophosphamide), Iressa (gefitinib), Gleevec (imatinib), oral Rheumatrex (oral methotrexate),

FDA warns of possible faulty test data  -  Jan 11, 2007
Science Daily (press release)...from AstraZeneca that a large clinical trial comparing Iressa (gefitinib) with placebo in patients with non-small cell lung cancer who had failed .

Telik share price plummets after cancer drug failure  -  Jan 3, 2007
DrugResearcher.com,...overall survival compared to AstraZeneca's now-withdrawn Iressa (gefitinib) in the third-line therapy of advanced non-small cell lung cancer (NSCLC).

Telik collapses as cancer drug fails three Phase III trials  -  Jan 1, 2007
Pharma Times (subscription),...goal of overall survival in a Phase III trial, called ASSIST-2, involving 520 patients with non-small cell lung cancer when compared to gefitinib.

Targeted Cancer Drugs May Work By Disrupting Balance Of Cellular ...  -  Dec 28, 2006
Science Daily (press release)...targets the BCR-ABL protein and both Tarceva and Iressa (gefitinib) inhibit EGFR activity -- have been very successful in limited numbers of patients.

Telik Reports Preliminary Results On ASSIST-1, ASSIST-2 And ASSIST ...  -  Dec 29, 2006
Medical News Today (press release),The ASSIST-2 trial, a 520 patient multinational, randomized study designed to evaluate TELCYTA as compared to gefitinib in the third-line therapy of

Cancer drug failure sinks Telik shares  -  Dec 27, 2006
Los Angeles Times,The lung cancer trial tested 520 patients, of whom some received Telcyta while others received a drug called gefitinib. The 440-patient ovarian cancer trial

Cancer Drug Fails Test, and the Company’s Stock Tumbles  -  Dec 26, 2006
New York Times,The lung cancer trial tested 520 patients, some of whom received Telcyta and others a drug called gefitinib. The 440-patient ovarian cancer trial tested

Telik's US shares dive on drug admission  -  Dec 26, 2006
Sydney Morning Herald,The lung cancer trial, known as ASSIST-2, tested 520 patients, of whom a portion received Telcyta and a portion received a drug called gefitinib.

Telik's leading cancer drug suffers setback  -  Dec 26, 2006
MarketWatchSpecifically, Telcyta missed its primary endpoint to improve overall survival in an Assist-2 trial involving comparison to gefitinib as a third-line therapy

Telik's Shares Take Tumble On Telcyta Phase III Failures  -  Dec 26, 2006
BioWorld Online,The second study, ASSIST-2, enrolled 520 patients and evaluated Telcyta as compared to gefitinib in the third-line therapy of advanced non-small-cell lung

Telik Thrashed After Cancer Drug Flunks Trials  -  Dec 26, 2006
Smartmoney.comTelik said its Assist-2 trial was designed to evaluate Telcyta as compared to gefitinib in the third-line therapy of advanced non-small cell lung cancer.

Telik cancer drug falls short in trials  -  Dec 26, 2006
United Press InternationalThe company said its ASSIST-2 trial, a 520-patient study comparing Telcyta with another drug gefitinib as a third-line therapy in patients with advanced

Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST ...  -  Dec 26, 2006
PR Newswire (press release),...a 520 patient multinational, randomized study designed to evaluate TELCYTA as compared to gefitinib in the third-line therapy of advanced non-small cell

Pharma Sector: Few Newsmakers Of The Week - Eli Lilly, Bristol ...  -  Dec 29, 2006
Trading Markets,The ASSIST-2 trial, a 520 patient multinational, randomized study, compared Telcyta to AstraZeneca's gefitinib in treating non-small cell lung cancer.

Telik Drug Disappoints  -  26 Dec 2006
TheStreet.comThe drug was compared with gefitinib, and it didn't achieve a statistically significant improvement in overall survival, the primary endpoint.

Cancer Drug Side Effect Caused By Cell Pump' Problem  -  Dec 10, 2006
Medical News Today (press release),However, mutant ABCG2 can be less efficient at pushing gefitinib out of cells in the intestine, the researchers noted. A buildup of drug within these cells

Oncology meet addresses lung cancer threat  -  Dec 2, 2006
Taipei Times,Huang Hsiu-feng ( 黃秀芬 ), a pathology researcher with the National Health Research Institute, recently discovered that the drug gefitinib, which has been

Genzyme launches lung-cancer gene test  -  Dec 4, 2006
United Press International...a marker linked to resistance to certain lung-cancer drugs, including the tyrosine kinase inhibitors Tarceva (erlotinib) and Iressa (gefitinib).

Genzyme Introduces New Genetic Test to Complement Lung Cancer ...  -  Dec 6, 2006
Oxfordshire Bioscience Network (press release),TKI therapies, such as Tarceva (erlotinib) and IRESSA (gefitinib), are currently used in NSCLC patients who are refractory, or have failed,

Cause of cancer drug side effects identified  -  Dec 7, 2006
Pharmaceutical Business Review..."Gefitinib represents a new type of treatment called targeted therapy, which researchers hoped would avoid causing significant side effects," said Sharyn

Genzyme Introduces New Genetic Test and Gilead Stock Jumps  -  Dec 5, 2006
Financial News USA (press release),...currently used in treating this deadly form of cancer, including the tyrosine kinase inhibitors (TKIs) Tarceva® (erlotinib) and IRESSA® (gefitinib).

New Genetic Test Predicts Response to Targeted Therapies  -  Dec 4, 2006
Genetic Engineering News (press release),...have been associated with resistance to certain drugs, including the tyrosine kinase inhibitors (TKIs) Tarceva® (erlotinib) and IRESSA® (gefitinib).

Role of Nexavar® in NSCLC Reviewed  -  Nov 30, 2006
Cancer Consultants (press release),The results of a phase I clinical trial evaluated the combination of Nexavar and Iressa® (gefitinib) for the treatment of 32 patients with refractory or

Iressa® Active and Well Tolerated in Advanced NSCLC Patients With ...  Oct 30, 2006
...that 75% of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations responded to Iressa (gefitinib). ... -Cancer Consultants (press release), Cancer :: Agencourt genomic services is key collaborator in new ...  Oct 16, 2006
Paez et.al. "EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy." Science, 4 June 2004, 1497 - 1500. Levine et al. ... -SpititIndia, Oncology Drug Development Update - Targeting the Epidermal Growth ...  Oct 10, 2006
Herceptin; Genentech), cetuximab (Erbitux; ImClone Systems); erlotinib (Tarceva; OSI Pharmaceuticals), and the now withdrawn gefitinib (Iressa; AstraZeneca ... -PR Newswire (press release), Lung cancer response to gefitinib predicted by good performance ...  Sep 21, 2006
Good performance status (PS) could predict response to gefitinib antitumor activity in Taiwanese lung cancer patients previously treated with chemotherapy. ... -Therapeutics Daily (subscription)

European Society for Medical Oncology - Press Program for the 31st ...  Sep 21, 2006
EGFR Mutations Can Help Predict Response To Gefitinib In Lung Cancer Lung cancer patients who have specific mutations in part of the gene for the cell surface ... -PR Newswire

New findings from the United Kingdom and United States in the area ...  Sep 14, 2006
Study 1: Estrogen receptor-positive breast cancers respond to therapy combining docetaxel and gefitinib. "We have evaluated the ... -Therapeutics Daily (subscription)

ASK THE DOCTOR  Sep 19, 2006
...kinase domain, which increases the likelihood of responding to drugs that block the EGFR pathway—such as Tarceva® (erlotinib) and Iressa® (gefitinib). ... -Cancer Consultants

Light Shed on Lung Cancer Drug-Resistance Mechanisms  Sep 6, 2006
...reported that they have identified a different mechanism that appears to confer on non-small-cell lung tumors resistance to Iressa (gefitinib) and Tarceva ... -MedPage Today

Glioma patients tolerated a combination of EGFR and mTOR ...  Sep 14, 2006
Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the ... -Therapeutics Daily (subscription)

Cancer drug talk may get shriller  Aug 25, 2006
AstraZeneca’s Iressa (gefitinib tablets), used against non-small-cell lung cancer (NSCLC), also costs more than Rs 1 lakh per patient, while treatment of ... -Daily News & Analysis

Health Canada Endorsed Important Safety Information on Iressa ...  -  12 Dec 2006
DG News...following discussions with Health Canada, is informing health care professionals of new safety information regarding Iressa (gefitinib).

Cancer Drug Side Effect Caused By Cell Pump' Problem  -  Dec 10, 2006
Medical News Today (press release),However, mutant ABCG2 can be less efficient at pushing gefitinib out of cells in the intestine, the researchers noted. A buildup of drug within these cells

Oncology meet addresses lung cancer threat  -  Dec 2, 2006
Taipei Times,Huang Hsiu-feng ( 黃秀芬 ), a pathology researcher with the National Health Research Institute, recently discovered that the drug gefitinib, which has been

Genzyme launches lung-cancer gene test  -  Dec 4, 2006
United Press International...a marker linked to resistance to certain lung-cancer drugs, including the tyrosine kinase inhibitors Tarceva (erlotinib) and Iressa (gefitinib).

Cancer drug shows greater efficacy in Taiwanese patients  -  Nov 13, 2006
Taiwan Headlines,..."We decided to do the study when we realized that Taiwanese patients were doing much better on Gefitinib than studies from abroad would predict," said Huang

APS: New Survival Study of Vandetanib (ZACTIMA(TM), ZD6474) in ...  -  Nov 16, 2006
ANP Pers Support,Bepler G. Lung cancer epidemiology and genetics. Journal of Thoracic Imaging . Natale R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib.

Genzyme Introduces New Genetic Test to Complement Lung Cancer ...  -  Dec 6, 2006
Oxfordshire Bioscience Network (press release),TKI therapies, such as Tarceva (erlotinib) and IRESSA (gefitinib), are currently used in NSCLC patients who are refractory, or have failed,

Cause of cancer drug side effects identified  -  Dec 7, 2006
Pharmaceutical Business Review..."Gefitinib represents a new type of treatment called targeted therapy, which researchers hoped would avoid causing significant side effects," said Sharyn

Genzyme Introduces New Genetic Test and Gilead Stock Jumps  -  Dec 5, 2006
Financial News USA (press release),...currently used in treating this deadly form of cancer, including the tyrosine kinase inhibitors (TKIs) Tarceva® (erlotinib) and IRESSA® (gefitinib).

New Genetic Test Predicts Response to Targeted Therapies  -  Dec 4, 2006
Genetic Engineering News (press release),...have been associated with resistance to certain drugs, including the tyrosine kinase inhibitors (TKIs) Tarceva® (erlotinib) and IRESSA® (gefitinib).

Role of Nexavar® in NSCLC Reviewed  -  Nov 30, 2006
Cancer Consultants (press release),The results of a phase I clinical trial evaluated the combination of Nexavar and Iressa® (gefitinib) for the treatment of 32 patients with refractory or

Targeted Cancer Drugs May Work By Disrupting Balance Of Cellular ...  -  Nov 17, 2006
Medical News Today (press release),...targets the BCR-ABL protein and both Tarceva and Iressa (gefitinib) inhibit EGFR activity - have been very successful in limited numbers of patients.

Women With Early Breast Cancer are More Likely to Remain Cancer ...  -  Nov 16, 2006
campus med,...'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed) and 'IRESSA' (gefitinib) as well as a range of novel targeted products such as anti-proliferatives,

New Survival Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients ...  -  Nov 16, 2006
campus med,A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa(TM)) in patients with NSCLC: results of a randomized, double-blind Phase II study.

Data from the United Kingdom, United States and Scotland advance ...  Aug 24, 2006
Study 1: Estrogen receptor-positive breast cancers respond to therapy combining docetaxel and gefitinib. "We have evaluated the ... -Therapeutics Daily (subscription)

Cancer drug talk may get shriller  Aug 25, 2006
AstraZeneca’s Iressa (gefitinib tablets), used against non-small-cell lung cancer (NSCLC), also costs more than Rs 1 lakh per patient, while treatment of ... -Daily News & Analysis

International Approvals: NovoRapid, TheraCIM, Nexavar  Aug 7, 2006
...antibody is a specific and active inhibitor of EGFr tyrosine kinase phosphorylation, a mechanism of action that is similar to that of gefitinib (Iressa, made ... -Medscape (subscription)

Access before Approval — A Right to Take Experimental Drugs?  Aug 2, 2006
Burroughs had tried unsuccessfully to obtain cetuximab (Erbitux) or gefitinib (Iressa), which were undergoing clinical trials and were recommended by Abigail's ... -New England Journal of Medicine (subscription)



AstraZeneca to buy Cambridge Antibody Tech  May 15, 2006
...of new drugs after a series of recent failures in late stage development, including Exanta (ximelegatran) for blood clots and Iressa (gefitinib) for lung ... - Pharma Times (subscription)

AV-412 demonstrates potent antitumor activity in preclinical ...  May 2, 2006
...anticancer compound AV-412 demonstrated potent antitumor activity against tumors that were sensitive to treatment with Tarceva (erlotinib) and Iressa (gefitinib ... - Therapeutics Daily (subscription)

Lung cancer: It's not just for smokers  May 7, 2006
Compelling examples include gefitinib and erlotinib, drugs targeted at specific growth-factor proteins found in many lung cancers. ... - Boston Globe

BACK ROADS JOHANNA D. WILSON Peach of a cat is one woman's cure  Apr 25, 2006
After my regular medicine, she is my medicine.". The other remedy to which she refers is gefitinib, marketed as Iressa - an anti-cancer drug. ... - Centre Daily Times

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional